Prelude Therapeutics
NASDAQ: PRLDNewark, US · Founded 2016 · Delaware corporation · 101 employees on LinkedIn · 2 known investors
Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors. It also applies targeted protein degradation expertise to develop next-generation degrader antibody conjugates (DACs).
Founders & leadership
Prelude Therapeutics was founded in 2016 by Krishna Vaddi.
KV
Krishna VaddiFounder
Board
DB
PF
Paul FriedmanDirector of Issuer
Investors · 2
Reported raises · per SEC filings
Form D private placements$115M disclosed across 4 rounds · 2016–2020
▶$50MraisedAug 2020 · 7 investors · BiotechnologyRule 506(b)
▶$50MraisedAug 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BonitaDirector
- Victor SandorDirector
- Peggy ScherleExecutive Officer
- Christopher PierceExecutive Officer
- Deborah MorosiniExecutive Officer
- Krishna VaddiExecutive Officer, Director
- Brian PiperExecutive Officer
- Mardi C. DierDirector
- Paul FriedmanDirector
- Kelvin NeuDirector
- David MauroExecutive Officer
- Andrew CombsExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$30MraisedJun 2019 · 6 investors · BiotechnologyRule 506(b)
▶$30MraisedJun 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krishna VaddiExecutive Officer, Director
- David MauroExecutive Officer
- Peggy ScherleExecutive Officer
- Kelvin NeuDirector
- David BonitaDirector
- Paul FriedmanDirector
- Offering amount
- $60M
- Amount sold
- $30M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$30MraisedAug 2018 · 7 investors · BiotechnologyRule 506(b)
▶$30MraisedAug 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Juan LuengoExecutive Officer
- David BonitaDirector
- Paul FriedmanDirector
- Kelvin NeuDirector
- Krishna VaddiExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$5MraisedJul 2016 · 8 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2016 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krishna VaddiExecutive Officer, Director
- Paul FriedmanDirector
- David BonitaDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapApplied Therapeutics32 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha31 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Prelude Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Prelude Therapeutics do?
- Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors. It also applies targeted protein degradation expertise to develop next-generation degrader antibody conjugates (DACs).
- Who founded Prelude Therapeutics?
- Prelude Therapeutics was founded by Krishna Vaddi in 2016.
- Who are Prelude Therapeutics's investors?
- Prelude Therapeutics's investors include OrbiMed, The Innovation Space.
- How much funding has Prelude Therapeutics raised?
- Prelude Therapeutics has disclosed $115M raised across 4 rounds.
- Where is Prelude Therapeutics headquartered?
- Prelude Therapeutics is headquartered in Newark, US.